The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases

被引:199
作者
Ross, CA
Pickart, CM
机构
[1] Johns Hopkins Univ, Sch Med, Div Neurobiol, Dept Psychiat, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA
关键词
D O I
10.1016/j.tcb.2004.10.006
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
During the past decade, it has become apparent that a set of ostensibly unrelated neurodegenerative diseases, including Parkinson's disease and Huntington's disease, shares striking molecular and cell biology commonalities. Each of the diseases involves protein misfolding and aggregation, resulting in inclusion bodies and other aggregates within cells. These aggregates often contain ubiquitin, which is the signal for proteolysis by the 26S proteasome, and chaperone proteins that are involved in the refolding of misfolded proteins. The link between the ubiquitin-proteasome system and neurodegeneration has been strengthened by the identification of disease-causing mutations in genes coding for several ubiquitin-proteasome pathway proteins in Parkinson's disease. However, the exact molecular connections between these systems and pathogenesis remain uncertain and controversial. In this article, we summarize the state of current knowledge, focusing on important unresolved questions.
引用
收藏
页码:703 / 711
页数:9
相关论文
共 95 条
[1]   Proteasome inhibitors as new anticancer drugs [J].
Adams, J .
CURRENT OPINION IN ONCOLOGY, 2002, 14 (06) :628-634
[2]   Impairment of the ubiquitin-proteasome system by protein aggregation [J].
Bence, NF ;
Sampat, RM ;
Kopito, RR .
SCIENCE, 2001, 292 (5521) :1552-1555
[3]   Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration [J].
Berke, SJS ;
Paulson, HL .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2003, 13 (03) :253-261
[4]   Diseases of protein conformation:: what do in vitro experiments tell us about in vivo diseases? [J].
Buxbaum, JN .
TRENDS IN BIOCHEMICAL SCIENCES, 2003, 28 (11) :585-592
[5]   Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways [J].
Chai, YH ;
Berke, SS ;
Cohen, RE ;
Paulson, HL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (05) :3605-3611
[6]   Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity [J].
Chen, S ;
Berthelier, V ;
Yang, W ;
Wetzel, R .
JOURNAL OF MOLECULAR BIOLOGY, 2001, 311 (01) :173-182
[7]   Amyloid-like features of polyglutamine aggregates and their assembly kinetics [J].
Chen, SM ;
Berthelier, V ;
Hamilton, JB ;
O'Nuallain, B ;
Wetzel, R .
BIOCHEMISTRY, 2002, 41 (23) :7391-7399
[8]   S-nitrosylation of Parkin regulates ubiquitination and compromises Parkin's protective function [J].
Chung, KKK ;
Thomas, B ;
Li, XJ ;
Pletnikova, O ;
Troncoso, JC ;
Marsh, L ;
Dawson, VL ;
Dawson, TM .
SCIENCE, 2004, 304 (5675) :1328-1331
[9]   Parkin ubiquitinates the α-synuclein-interacting protein, synphilin-1:: implications for Lewy-body formation in Parkinson disease [J].
Chung, KKK ;
Zhang, Y ;
Lim, KL ;
Tanaka, Y ;
Huang, H ;
Gao, J ;
Ross, CA ;
Dawson, VL ;
Dawson, TM .
NATURE MEDICINE, 2001, 7 (10) :1144-1150
[10]   Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct [J].
Conway, KA ;
Rochet, JC ;
Bieganski, RM ;
Lansbury, PT .
SCIENCE, 2001, 294 (5545) :1346-1349